No videos found.
Lilly's AJ1-11095 hit 70% spleen volume reduction in post-ruxolitinib patients at EHA 2026, threatening Incyte's $1.5B ruxolitinib franchise with...
60 Degrees Pharma licenses Australian Chestnut Extract from Florida State University for supplement development, pending FDA safety clarification.
Simcere Pharmaceutical partners with Stanford on IPF therapy using LYTAC technology to target protein degradation beyond current treatment limits.
Sanofi's Tzield just won FDA approval for stage 3 T1D, threatening insulin's 68% grip on a $28.6B market and...
VERAXA Biotech launches on Nasdaq with $77.5M financing for BiTAC Platform, designed to reduce toxicity in T-cell engagers for...
Neion Bio raises $23M Series A for egg-based protein manufacturing platform targeting recombinant biologics production.
Adial Pharmaceuticals acquires Azora Therapeutics for $64M to develop AT177, an indirubin prodrug targeting ulcerative colitis through localized colon...
Roche's FDA Priority Review for Tecentriq in dMMR/MSI-H stage III colon cancer has an October 9 decision date. Here's...
Biotech VC hit $26B in 2024 as IPOs lagged and China licensing surged—here's what the recovery's structure reveals about...
BridgeBio partners with DKSH to distribute Attruby in Asia Pacific markets including Australia, Singapore, South Korea, and Taiwan.
